This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cryz, S. J. Articles by Kollaritsch, H. Search for Related Content PubMed PubMed Citation Articles by Cryz, S. J., Jr Articles by Kollaritsch, H.

 Previous Article  |  Next Article 

Infect. Immun., Apr 1995, 1336-1339, Vol 63, No. 4
Copyright © 1995, American Society for Microbiology

Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults

SJ Cryz Jr, JU Que, MM Levine, G Wiedermann and H Kollaritsch
Swiss Serum and Vaccine Institute, Berne.

The safety and immunogenicity of the live oral attenuated vaccine strains vibrio cholerae CVD 103-HgR and Salmonella typhi Ty21a were evaluated alone or in a combined bivalent formulation in four groups composed of 185 healthy European adults. All presentations were well tolerated. The serum anti-S. typhi lipopolysaccharide immunoglobulin G and immunoglobulin A antibody responses were comparable for all groups (66 to 72% seroconversion). The serum vibriocidal antibody seroconversion rate ranged from 78 to 92.5% (P > 0.05) among the groups. However, the peak and geometric mean vibriocidal antibody titers were significantly higher (P < 0.005) in the groups which received the bivalent formulation along with two doses of Ty21a than in the group which received CVD 103-HgR followed by two doses of killed Escherichia coli K-12 placebo. The ingestion of a placebo shortly after CVD 103-HgR may have suppressed the magnitude of the immune response. These findings demonstrate the feasibility of producing multivalent live oral attenuated vaccines.

This article has been cited by other articles:

• Viret, J.-F., Favre, D., Wegmuller, B., Herzog, C., Que, J. U., Cryz, S. J. Jr., Lang, A. B. (1999). Mucosal and Systemic Immune Responses in Humans after Primary and Booster Immunizations with Orally Administered Invasive and Noninvasive Live Attenuated Bacteria. Infect. Immun. 67: 3680-3685 [Abstract] [Full Text]  
• Engels, E. A, Falagas, M. E, Lau, J., Bennish, M. L (1998). Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ 316: 110-116 [Abstract] [Full Text]